Bayer to spend almost $700M on German sites for hemophilia drugs

03/13/2014 | PharmaTimes (U.K.) · Reuters

Bayer plans to spend nearly $700 million to expand production capacity at its Wuppertal and Leverkusen sites in Germany, where it plans to manufacture its two experimental hemophilia A drugs. Both drugs, BAY 81-8973 and BAY 94-9027, are in late-stage trials. Bayer said the investment would create about 500 new jobs at the two sites by 2020.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN